U.S. Markets close in 5 hrs 34 mins

  • S&P 500

    4,410.13
    +12.19 (+0.28%)
     

  • Dow 30

    34,364.50
    +99.10 (+0.29%)
     

  • Nasdaq

    13,855.10
    +86.23 (+0.63%)
     

  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     

  • Crude Oil

    0 (0)
     

  • Gold

    1,841.10
    -0.60 (-0.03%)
     

  • Silver

    23.83
    +0.03 (+0.11%)
     

  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     

  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     

  • Vix

    28.85
    +3.26 (+12.74%)
     

  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     

  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     

  • BTC-USD

    36,393.42
    +2,874.53 (+8.58%)
     

  • CMC Crypto 200

    823.79
    +13.18 (+1.63%)
     

  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     

  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Yahoo Finance/Decrypt: Crypto Goes Mainstream

Join us here for Crypto Goes Mainstream on Tuesday November 9th, from 1:00pm to 5:30pmET. Yahoo Finance and Decrypt present an afternoon of live conversations with some of the biggest names in crypto to talk investing, mass adoption, NFT collecting, and how to get started. Don't miss hearing from speakers like FTX CEO Sam Bankman-Fried, Robinhood Crypto COO Christine Brown, Solana founder Anatoly Yakovenko, VaynerMedia CEO Gary Vaynerchuk, and many more. For information or questions about this or other Yahoo Finance events, including speaking and sponsorship opportunities, please email AMS@YAHOOFINANCE.COM.

Recommended Stories

  • Why Sierra Oncology Stock Is On Fire Today

    Shares of the clinical-stage biotech Sierra Oncology (NASDAQ: SRRA) jumped by as much as 90% in premarket trading Tuesday. Investors are piling into this small-cap biotech stock today in response to overwhelmingly positive late-stage trial results for the blood cancer drug candidate momelotinib. Specifically, Sierra announced ahead of the opening bell Tuesday morning that momelotinib met all of its primary and secondary endpoints in a phase 3 trial as a treatment for myelofibrosis patients who are symptomatic and anemic and were previously treated with an approved JAK inhibitor.

  • 5 Reasons to Sell Plug Power Stock in 2022

    Despite nearly a decade of development, the fuel cell maker's future remains uncertain and unprofitable.

  • Is Shopify Stock a Buy Now?

    E-commerce giant Shopify (NYSE: SHOP) has been a market darling, appreciating more than 3,000% since going public in 2015. Why is Shopify's stock price falling? There are a few potential things to point to in Shopify's case.

  • Down 57% in 1 Month, Is Novavax a Bargain Buy?

    To say that Novavax (NASDAQ: NVAX) investors haven't had a smooth ride recently is a massive understatement. Amid a string of successes (and a few setbacks) in getting its coronavirus vaccine, Nuvaxovid approved by regulators in the European Union, South Korea, and with the World Health Organization, the company's stock has plummeted, falling around 55% compared to its price six months ago and 57% since a mere 30 days ago. Has the stock fallen enough to be worth a purchase based on the expectation of future jab sales and vaccine development, or should investors stay away for the time being?

  • Beware: This SPAC Bubble Stock Could Burst in 2022

    Former President Donald Trump is starting a social media network and streaming service called Truth Social and TMTG+, respectively, taking the companies public under Trump Media & Technology Group in a SPAC merger with Digital World Acquisition (NASDAQ: DWAC). Trump's headbutting with large media companies has been well-publicized, including his banishment from social media platforms like Twitter and Facebook (owned by Meta Platforms).

  • These five signals will tell you when the Wall Street correction is over, says veteran strategist

    Barry Bannister and the team at Stifel say investors should be wary of any late-day rallies from a stock market that has miles to go before its correction phase is over.

  • GE's shares fall as supply-chain woes hit Q4 revenue

    The Boston-based industrial conglomerate said it was facing supply-chain issues across all of its businesses, but the problem remained most acute at its healthcare unit. They are also fueling inflationary pressure, adversely impacting its onshore wind business due to the rising cost of transportation and commodities like steel. In response, Chief Executive Larry Culp told investors that the company was raising prices and trying to keep a lid on costs.

  • Three Market Gurus Tell You Exactly When Stocks Will Stop Falling

    Watching trillions of dollars evaporate gets the imagination reeling. Already three strategists try to find when the S&P 500 might bottom.

  • Stocks: GE declines on revenue miss, 3M climbs on earnings beat, IBM boosted by sales growth

    Yahoo Finance's Julie Hyman and Brian Sozzi review recent earnings reports from General Electric, 3M, and IBM.

  • White House to enter crypto regulation fray, with eye on financial stability

    The Biden administration is preparing to release a government-wide strategy to regulate crypto as early as February

  • NFL’s Odell Beckham Jr. took his $750,000 salary in bitcoin — how much did that end up costing him?

    Beckham announced in November that he planned to convert his salary for this NFL season into bitcoin

  • IBM stock rises after topping Q4 estimates

    Yahoo Finance's Jared Blikre details IBM's Q4 earnings report in which it beats estimates.

  • My 3 Favorite Growth Stocks to Buy in January

    January has not been kind to growth stocks. Longtime investors know that short-term volatility is simply the price of admission for the outsized returns that many growth stocks can produce over the long term. Ford Motor Company (NYSE: F), ChargePoint Holdings (NYSE: CHPT), and Block (NYSE: SQ) are three growth stocks worth considering for patient investors that can stomach more pain in case the stock market keeps falling.

  • Why Nio Stock Is Sinking Today

    Shares of Chinese electric-vehicle maker Nio (NYSE: NIO) opened sharply lower in U.S. trading on Monday amid a broad market sell-off triggered by rising global tensions and interest rate fears ahead of a key U.S. Federal Reserve meeting. As of 10:15 a.m. ET, Nio's American depositary shares were down about 11.9% from Friday's closing price. Nio was just one of many companies that saw their shares hit hard in early trading on Monday.

  • 3 Top Stocks That Can Make You Richer in January (and Beyond)

    Despite recent volatility, Wall Street and investors have enjoyed a record-breaking run. The benchmark S&P 500 took less than 17 months to double off of its coronavirus pandemic lows set in March 2020, and the index logged nearly six dozen record-closing highs last year. The first top stock that could make you richer in January and well beyond is biotech stock Novavax (NASDAQ: NVAX).

  • These 4 Dow Stocks Are Screaming Buys in 2022

    The 125-year-old Dow Jones Industrial Average is home to these four exceptional growth and value stocks.

  • GE Misses Sales Expectations in Setback for Larry Culp’s Turnaround

    (Bloomberg) -- General Electric Co. missed Wall Street’s sales expectations for the fourth quarter as it grappled with worsening supply-chain pressures, a stumble for Chief Executive Officer Larry Culp as he readies a plan to break up the conglomerate.Most Read from BloombergStocks Storm Back From 4% Rout to Close Higher: Markets WrapS&P 500 Slumps 2% Amid Fed, Russia-Ukraine Jitters: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidBiden Has ‘Great Meeting’ With European Leader

  • Inflation at 7%: 3 Top Dividend Stocks to Protect Your Money

    The Bureau of Labor Statistics' recently published consumer price index (CPI) report showed that inflation rose 7% from 2020, its highest jump since 1982. With that in mind, a panel of Motley Fool contributors has identified three stocks that can help you thrive through inflation. Read on to see why they think Procter & Gamble (NYSE: PG), JPMorgan Chase (NYSE: JPM), and Broadcom (NASDAQ: AVGO) are top buys right now.

  • Verizon beats earnings expectations, gives upbeat outlook

    Verizon Communications Inc. exceeded earnings estimates for the most recent quarter while giving an upbeat earnings outlook for the full year ahead.

  • Surprised by Monday’s market recovery? Whenever the Dow and the S&P 500 fall below this key support level, stocks typically come roaring back

    The U.S. market breached its 200-day moving average last week and, true to form, quickly reversed course and rallied.